All-In Podcast · · 56 min

WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight

With Will Ahmed

Summary

WHOOP CEO Will Ahmed explains how the company moved from a $500 upfront device to a monthly membership, arguing that the subscription lowered the entry barrier and turned WHOOP into a recurring-revenue business that avoids the annual hardware-refresh cycle. He describes the health data moat: members wear the device about 23.6 hours a day, generating over 50 billion hours of physiological data, which WHOOP combines with uploaded blood tests and medical records to train its models and an AI coach. Ahmed gives membership milestones (1 million after about 12 years, 2 million, 3 million, with roughly 4 million expected by year-end) and says WHOOP tailors activity and protein/strength targets for GLP-1 users to limit muscle loss. On regulation, he defends WHOOP's blood pressure insights feature against an FDA warning letter, arguing a wellness lane exists and crediting the FDA's later guidance update partly to WHOOP's pushback, and he contrasts WHOOP's no-data-selling subscription model with ad-funded big tech. Ahmed and Jason Calacanis also dismiss unsolicited secondary share brokers as fishing expeditions, based on their own experience.

Key takeaways

  • Will Ahmed on GLP-1s & obesity drugs: GLP-1 users lose muscle as well as fat, so they need activity, strength training and protein to avoid frailty.
  • Will Ahmed on Venture capital & startups: Secondary share brokers often claim shares they don't have and are mainly trying to create a market.
  • Jason Calacanis on Venture capital & startups: Secondary brokers pitching shares in private companies are mostly fishing, since they rarely follow through.

What was said, by company and theme

3 views from 2 speakers. Every quote is checked against the episode's transcript (how).

Venture capital & startups

  • Will Ahmed · WHOOP

    Secondary share brokers often claim shares they don't have and are mainly trying to create a market.

    Ahmed says secondary brokers claim to hold shares from a specific holder at a stated price. In his view, they go around making those claims, but their real aim is to create a market for the shares rather than to complete a verified transaction. The point is based on his experience with such brokers, not on hard data.

    “They claim they've got shares from someone at a price... And they go around saying that, but they're really just trying to create a market.”at 53:52
  • Jason Calacanis · LAUNCH

    Secondary brokers pitching shares in private companies are mostly fishing, since they rarely follow through.

    Calacanis, who says he sits on the board of a company worth a couple of billion dollars, describes brokers who approach him claiming to have shares. When he asks who is selling so he can coordinate with the CFO, they go quiet. He concludes that these approaches are fishing expeditions. He adds that this kind of secondary trading barely existed 10 to 15 years ago. His evidence is his own repeated experience rather than market data.

    “I'm on the board of a company that's worth a couple billion dollars, and they come to me and I say, okay. Great. Who who is it with? ... And then crickets. And I'm like, they're fishing. It's always a fishing expedition.”at 54:07

GLP-1s & obesity drugs

  • Will Ahmed · WHOOP

    GLP-1 users lose muscle as well as fat, so they need activity, strength training and protein to avoid frailty.

    Ahmed says that typically about 50% of the weight a GLP-1 user loses is fat and 50% is muscle, which can leave people frail even after a large weight loss. He argues that WHOOP knowing a member is on a GLP-1 lets it push activity and some strength training, even bodyweight work, to preserve muscle. He points to a proper diet with protein and anecdotal success with creatine as important. This is why WHOOP built a GLP-1 tracker that sets protein, strength and step targets.

    “is that typically speaking about 50% of the weight that someone loses is fat and 50% is muscle.”at 33:07

Topics

  • FDA regulation of wearables
  • ad-funded versus subscription business models
  • health data moat
  • membership growth
  • muscle loss on GLP-1s
  • secondary share brokers
  • wearable subscription model

More from All-In Podcast

All All-In Podcast episodes

Ask your AI about this episode

Chorus gives Claude, ChatGPT and other assistants every view from this episode and the rest of the market's podcasts. Ask who agrees, who changed their mind, and what else was said about the same companies.

Setup guide

Chorus reports what speakers said. It isn't investment advice. How Chorus works · About Chorus